Trial Profile
A phase III, multicenter, double-blind, placebo controlled, non-inferiority study assessing the effects of ciclesonide metered dose inhaler 50 mg/day and 200 mg/day (ex-valve) administered once daily on growth in children with mild persistent asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Sanofi
- 22 Sep 2006 New trial record.